Trials / Completed
CompletedNCT00707304
Safety and Efficacy of Talactoferrin in Previously Treated Patients With Non-small Cell Lung Cancer
FORTIS-M: A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Oral Talactoferrin in Addition to Best Supportive Care in Patients With Non-small Cell Lung Cancer Who Have Failed Two or More Prior Treatment Regimens
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 742 (actual)
- Sponsor
- Agennix · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether talactoferrin can improve overall survival in patients with non-small cell lung cancer (NSCLC) who have been previously treated with two or more regimens.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Talactoferrin | Oral, 1.5 grams twice per day |
| DRUG | Placebo | Oral, twice per day |
Timeline
- Start date
- 2008-11-01
- Primary completion
- 2011-03-01
- Completion
- 2012-08-01
- First posted
- 2008-06-30
- Last updated
- 2012-08-21
Locations
189 sites across 23 countries: United States, Australia, Bulgaria, Canada, Czechia, France, Germany, Greece, Hungary, India, Italy, Latvia, Malaysia, Philippines, Poland, Romania, Russia, Singapore, South Korea, Spain, Taiwan, Turkey (Türkiye), United Kingdom
Source: ClinicalTrials.gov record NCT00707304. Inclusion in this directory is not an endorsement.